Resonant Capital Advisors LLC boosted its stake in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 7.2% within the second quarter, Holdings Channel stories. The fund owned 2,946 shares of the medical analysis firm’s inventory after buying a further 199 shares in the course of the interval. Resonant Capital Advisors LLC’s holdings in Edwards Lifesciences have been value $272,000 as of its most up-to-date submitting with the Securities and Trade Fee.
Quite a few different hedge funds additionally just lately added to or lowered their stakes in EW. DSM Capital Companions LLC acquired a brand new stake in Edwards Lifesciences in the course of the 4th quarter value roughly $28,000. Crewe Advisors LLC acquired a brand new stake in Edwards Lifesciences in the course of the 1st quarter value roughly $28,000. First Neighborhood Belief NA acquired a brand new stake in shares of Edwards Lifesciences within the 2nd quarter valued at roughly $29,000. Riverview Belief Co acquired a brand new stake in shares of Edwards Lifesciences within the 1st quarter valued at roughly $34,000. Lastly, Pingora Companions LLC acquired a brand new stake in shares of Edwards Lifesciences within the 4th quarter valued at roughly $38,000. 79.46% of the inventory is owned by institutional traders and hedge funds.
Edwards Lifesciences Worth Efficiency
EW inventory opened at $68.75 on Wednesday. The inventory has a 50-day shifting common worth of $76.26 and a two-hundred day shifting common worth of $84.54. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month excessive of $96.12. The corporate has a present ratio of three.71, a fast ratio of two.87 and a debt-to-equity ratio of 0.08. The corporate has a market cap of $41.43 billion, a PE ratio of 29.63, a price-to-earnings-growth ratio of two.92 and a beta of 1.11.
Edwards Lifesciences (NYSE:EW – Get Free Report) final issued its quarterly earnings knowledge on Wednesday, July twenty fourth. The medical analysis firm reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. The corporate had income of $1.63 billion for the quarter, in comparison with analysts’ expectations of $1.65 billion. Edwards Lifesciences had a return on fairness of twenty-two.35% and a web margin of 24.55%. The agency’s quarterly income was up 6.7% on a year-over-year foundation. Throughout the identical quarter within the earlier yr, the agency posted $0.66 earnings per share. As a gaggle, analysis analysts predict that Edwards Lifesciences Co. will put up 2.7 EPS for the present yr.
Insiders Place Their Bets
In different Edwards Lifesciences information, VP Donald E. Bobo, Jr. bought 5,000 shares of the enterprise’s inventory in a transaction dated Wednesday, July tenth. The inventory was bought at a mean worth of $93.29, for a complete transaction of $466,450.00. Following the transaction, the vice chairman now owns 46,936 shares within the firm, valued at $4,378,659.44. The sale was disclosed in a authorized submitting with the SEC, which is on the market at the SEC web site. In different Edwards Lifesciences information, VP Donald E. Bobo, Jr. bought 5,000 shares of the enterprise’s inventory in a transaction dated Wednesday, July tenth. The inventory was bought at a mean worth of $93.29, for a complete transaction of $466,450.00. Following the transaction, the vice chairman now owns 46,936 shares within the firm, valued at $4,378,659.44. The sale was disclosed in a authorized submitting with the SEC, which is on the market at the SEC web site. Additionally, VP Daveen Chopra bought 1,250 shares of the enterprise’s inventory in a transaction dated Tuesday, August twentieth. The inventory was bought at a mean worth of $69.95, for a complete worth of $87,437.50. Following the completion of the transaction, the vice chairman now owns 29,333 shares within the firm, valued at roughly $2,051,843.35. The disclosure for this sale might be discovered right here. Insiders have bought a complete of 16,250 shares of firm inventory value $1,321,988 during the last quarter. 1.29% of the inventory is owned by company insiders.
Analyst Upgrades and Downgrades
EW has been the topic of a number of latest analyst stories. Robert W. Baird reduce Edwards Lifesciences from an “outperform” score to a “impartial” score and lowered their worth goal for the corporate from $102.00 to $70.00 in a report on Thursday, July twenty fifth. Truist Monetary reduce Edwards Lifesciences from a “purchase” score to a “maintain” score and lowered their worth goal for the corporate from $110.00 to $82.00 in a report on Thursday, July twenty fifth. StockNews.com reduce Edwards Lifesciences from a “purchase” score to a “maintain” score in a report on Thursday, July twenty fifth. Barclays lowered their worth goal on Edwards Lifesciences from $101.00 to $90.00 and set an “obese” score for the corporate in a report on Friday, July twenty sixth. Lastly, Baird R W reduce Edwards Lifesciences from a “strong-buy” score to a “maintain” score in a report on Thursday, July twenty fifth. Fourteen analysis analysts have rated the inventory with a maintain score, eleven have given a purchase score and one has assigned a robust purchase score to the corporate. Based on MarketBeat.com, the inventory presently has a consensus score of “Average Purchase” and a mean worth goal of $82.10.
View Our Newest Inventory Report on Edwards Lifesciences
Edwards Lifesciences Profile
Edwards Lifesciences Company gives merchandise and applied sciences for structural coronary heart illness and important care monitoring in america, Europe, Japan, and internationally. It presents transcatheter coronary heart valve alternative merchandise for the minimally invasive alternative of aortic coronary heart valves underneath the Edwards SAPIEN household of valves system; and transcatheter coronary heart valve restore and alternative merchandise to deal with mitral and tricuspid valve illnesses underneath the PASCAL PRECISION and Cardioband names.
Learn Extra
Need to see what different hedge funds are holding EW? Go to HoldingsChannel.com to get the newest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EW – Free Report).
Obtain Information & Rankings for Edwards Lifesciences Each day – Enter your electronic mail deal with under to obtain a concise each day abstract of the newest information and analysts’ scores for Edwards Lifesciences and associated corporations with MarketBeat.com’s FREE each day electronic mail e-newsletter.
